Portal de Periódicos da CAPES

Emerging adult age status predicts poor buprenorphine treatment retention

2014; Elsevier BV; Volume: 47; Issue: 3 Linguagem: Inglês

10.1016/j.jsat.2014.04.006

1873-6483

Zev Schuman‐Olivier, Roger D. Weiss, Bettina B. Hoeppner, Jacob T. Borodovsky, Mark J. Albanese,

Prenatal Substance Exposure Effects

Abstract Emerging adults (18–25years old) are often poorly retained in substance use disorder treatment. Office-based buprenorphine often enhances treatment retention among people with opioid dependence. In this study, we examined the records of a collaborative care buprenorphine treatment program to compare the treatment retention rates of emerging adults versus older adults. Subjects were 294 adults, 71 (24%) aged 18–25, followed in treatment with buprenorphine, nurse care management, and an intensive outpatient program followed by weekly psychosocial treatment. Compared to older adults, emerging adults remained in treatment at a significantly lower rate at 3months (56% versus 78%) and 12months (17% versus 45%), and were significantly more likely to test positive for illicit opioids, relapse, or drop out of treatment. Further research into factors associated with buprenorphine treatment retention among emerging adults is needed to improve treatment and long-term outcomes in this group.